Abstract: Inventions herein described relate to methods, devices and kits for detecting viral infections, particularly COVID-19 infections by the SARs-CoV2 corona virus. Various aspects of the inventions relate to serological antibody tests, particularly those that reduce false positive. Additionally, various aspects relate to serological detection of acute phase immune responses and distinguishing them from later phase response. Additional aspects relate to detection of antibodies indicative of natural COVID-19 virus infection even if the sample is from a vaccinated individual.

Abstract: The application describes methods for detecting site specific proteases indicative of infection by a protease-generating pathogen. The application also describes fusion proteins for use in the methods, DNAs encoding the proteins and cells that express them. Particular applications are described including fusion proteins and methods for detecting corona viruses,. such as SARS CoV2. Method for protease and pathogen detection described in the application include protease amplification methods and methods using inhibitors to increase sensitivity and specificity.

Abstract: The present invention relates to reagents and methods for influenza virus detection. These reagents and methods disclosed in the present invention enable simple, rapid, specific and sensitive detection of influenza virus types A and B. These reagents are N-acetylneuraminic acid-firefly luciferin conjugates which can be cleaved by influenza virus neuraminidase.

Abstract: The present invention relates to reagents and methods for influenza virus detection. These reagents and methods disclosed in the present invention enable simple, rapid, specific and sensitive detection of influenza virus types A and B. These reagents are N-acetylneuraminic acid-firefly luciferin conjugates which can be cleaved by influenza virus neuraminidase.